

Strategies and Molecular Probes to Investigate the Role of Metabolism

Clinical Pharmacokinetics

42, 153-178

DOI: [10.2165/00003088-200342020-00004](https://doi.org/10.2165/00003088-200342020-00004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	CRYOPRESERVED HUMAN HEPATOCYTES AS ALTERNATIVE IN VITRO MODEL FOR CYTOCHROME P450 INDUCTION STUDIES. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2003, 39, 283.	0.7	32
2	DIFFERENTIATION OF GUT AND HEPATIC FIRST-PASS LOSS OF VERAPAMIL IN INTESTINAL AND VASCULAR ACCESS-PORTED (IVAP) RABBITS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1293-1298.	1.7	21
3	Use of a cocktail of probe substrates for drug-metabolizing enzymes for the assessment of the metabolic capacity of hepatocyte preparations. <i>Xenobiotica</i> , 2004, 34, 949-959.	0.5	20
4	Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. <i>European Journal of Pharmaceutical Sciences</i> , 2004, 23, 189-199.	1.9	52
5	Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19. <i>Biochemical Pharmacology</i> , 2004, 68, 165-175.	2.0	19
6	The use of <i>Yarrowia lipolytica</i> for the expression of human cytochrome P450 CYP1A1. <i>Yeast</i> , 2004, 21, 583-592.	0.8	49
7	Human Carbonyl Reduction Pathways and a Strategy for Their Study In Vitro. <i>Drug Metabolism Reviews</i> , 2004, 36, 335-361.	1.5	67
8	Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes. <i>Archives of Biochemistry and Biophysics</i> , 2004, 424, 226-234.	1.4	55
9	Alfentanil-Induced Miosis Clearance as a Liver CYP3A4 and 3A5 Activity Measure in Healthy Volunteers: Improvement of Experimental Conditions. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1434-1441.	1.0	6
10	Adverse Drug Reactions and Interactions: Mechanisms, Risk Factors, Detection, Management and Prevention. , 2005, , 91-125.		0
11	Predicting in vivo drug interactions from in vitro drug discovery data. <i>Nature Reviews Drug Discovery</i> , 2005, 4, 825-833.	21.5	761
12	Prediction of Drug Metabolism and Interactions on the Basis of in vitro Investigations. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 96, 167-175.	1.2	122
13	Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. <i>Journal of Nutritional Biochemistry</i> , 2005, 16, 449-466.	1.9	420
14	Cytochrome P450 3A Expression and Activity in the Rabbit Lacrimal Gland: Glucocorticoid Modulation and the Impact on Androgen Metabolism. , 2005, 46, 4697.		13
15	A Microtiterplate-Based Screening Assay to Assess Diverse Effects on Cytochrome P450 Enzyme Activities in Primary Rat Hepatocytes by Various Compounds. <i>Assay and Drug Development Technologies</i> , 2005, 3, 27-38.	0.6	13
16	Antimycotic Drug Discovery in the Age of Genomics. <i>Molecular Diagnosis and Therapy</i> , 2005, 5, 365-386.	3.3	3
17	Applications of AmpliChip®, CYP450. <i>Molecular Diagnosis and Therapy</i> , 2005, 9, 119-127.	1.2	13
18	Naringenin-type flavonoids show different estrogenic effects in mammalian and teleost test systems. <i>Biochemical and Biophysical Research Communications</i> , 2005, 326, 909-916.	1.0	30

#	ARTICLE	IF	CITATIONS
19	GLUCURONIDATION AND SULFATION OF 7-HYDROXYCOUMARIN IN LIVER MATRICES FROM HUMAN, DOG, MONKEY, RAT, AND MOUSE. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2005, 41, 97.	0.7	36
20	Measurement of Xenobiotic Carbonyl Reduction in Human Liver Fractions. , 2005, Chapter 4, Unit4.17.		1
21	High-Throughput Physicochemical and In Vitro ADMET Screening. <i>American Journal of Drug Delivery</i> , 2005, 3, 83-100.	0.6	19
22	Contribution of CYP2C9, CYP2A6, and CYP2B6 to Valproic Acid Metabolism in Hepatic Microsomes from Individuals with the CYP2C9*1/*1 Genotype. <i>Toxicological Sciences</i> , 2006, 94, 261-271.	1.4	128
23	Cryopreserved human hepatocytes in suspension are a convenient high throughput tool for the prediction of metabolic clearance. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2006, 63, 347-355.	2.0	37
24	Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 183-212.	1.5	173
25	A prospective study of isolated human hepatocyte function following liver resection for colorectal liver metastases: The effects of prior exposure to chemotherapy. <i>Journal of Hepatology</i> , 2006, 45, 263-270.	1.8	26
26	Human Tissue for In Vitro Research as an Alternative to Animal Experiments: A Charitable "Honest Broker" Model to Fulfil Ethical and Legal Regulations and to Protect Research Participants. <i>ATLA Alternatives To Laboratory Animals</i> , 2006, 34, 387-392.	0.7	18
27	CYP3A4 activity in four different animal species liver microsomes using 7-benzyloxyquinoline and HPLC/spectrofluorometric determination. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2006, 40, 211-214.	1.4	14
28	Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N -Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 1130-1135.	1.4	57
29	Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy. <i>Clinical Microbiology Reviews</i> , 2006, 19, 763-787.	5.7	35
30	Determination of major human cytochrome P450s activities in 96-well plates using liquid chromatography tandem mass spectrometry. <i>Toxicology in Vitro</i> , 2007, 21, 1247-1252.	1.1	37
31	Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype This article is one of a selection of papers published in this special issue (part 1 of 2) on the Safety and Efficacy of Natural Health Products.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007, 85, 848-855.	0.7	13
32	The effect of selected metals on the central metabolic pathways in biology: A review. <i>Water S A</i> , 2007, 32, .	0.2	11
33	Effects of the Introduction of In Vitro Assays on the Use of Experimental Animals in Pharmacological Research. <i>ATLA Alternatives To Laboratory Animals</i> , 2007, 35, 223-228.	0.7	3
34	Rapid determination of six metabolites from multiple cytochrome P450 probe substrates in human liver microsome by liquid chromatography/mass spectrometry: application to high-throughput inhibition screening of terpenoids. <i>Rapid Communications in Mass Spectrometry</i> , 2007, 21, 635-643.	0.7	87
35	The use of a high-throughput luminescent method to assess CYP3A enzyme induction in cultured rat hepatocytes. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2008, 44, 129-134.	0.7	7
36	A new <i>in vitro</i> approach for the simultaneous determination of phase I and phase II enzymatic activities of human hepatocyte preparations. <i>Rapid Communications in Mass Spectrometry</i> , 2008, 22, 240-244.	0.7	24

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetics in Drug Discovery. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 654-690.	1.6	116
38	Pharmacogenetics of analgesics: toward the individualization of prescription. <i>Pharmacogenomics</i> , 2008, 9, 905-933.	0.6	91
39	An update on metabolism studies using human hepatocytes in primary culture. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2008, 4, 837-854.	1.5	66
40	Comparison of intrinsic metabolic clearance in fresh and cryopreserved human hepatocytes. <i>Xenobiotica</i> , 2009, 39, 656-662.	0.5	26
41	Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B ₅ . <i>Drug Metabolism and Disposition</i> , 2009, 37, 254-258.	1.7	58
42	Roles of Different CYP Enzymes in the Formation of Specific Fluvastatin Metabolites by Human Liver Microsomes. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 105, 327-332.	1.2	15
43	Microsomal cytochrome P450-3A4 (CYP3A4) nanobiosensor for the determination of 2,4-dichlorophenol—An endocrine disruptor compound. <i>Electrochimica Acta</i> , 2009, 54, 1925-1931.	2.6	39
44	Predicting the Clinical Relevance of Drug Interactions From Pre-Approval Studies. <i>Drug Safety</i> , 2009, 32, 1017-1039.	1.4	19
46	Liver Cell Culture Techniques. <i>Methods in Molecular Biology</i> , 2009, 481, 35-46.	0.4	39
47	Drug interactions. <i>Drug Metabolism Reviews</i> , 2009, 41, 486-527.	1.5	45
48	Prediction of human pharmacokinetics—evaluation of methods for prediction of hepatic metabolic clearance. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 803-828.	1.2	64
49	Validated assay for studying activity profiles of human liver UGTs after drug exposure: inhibition and induction studies. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 2251-2263.	1.9	57
50	Cytochrome P450 system as a toxicity biomarker of industrial wastewater in rat tissues. <i>Food and Chemical Toxicology</i> , 2010, 48, 998-1001.	1.8	30
51	Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. <i>Xenobiotica</i> , 2010, 40, 637-649.	0.5	100
52	Metabolic Barrier of the Gastrointestinal Tract*. , 2010, , 53-75.		2
53	HepaRG human hepatic cell line utility as a surrogate for primary human hepatocytes in drug metabolism assessment in vitro. <i>Journal of Pharmacological and Toxicological Methods</i> , 2011, 63, 59-68.	0.3	182
54	Primary rat hepatocyte culture on 3D nanofibrous polymer scaffolds for toxicology and pharmaceutical research. <i>Biotechnology and Bioengineering</i> , 2011, 108, 141-150.	1.7	66
55	Fenton's oxidation: A tool for the investigation of potential drug metabolites. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 54, 1047-1058.	1.4	20

#	ARTICLE	IF	CITATIONS
56	Sex Differences in Drug Disposition. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-14.	3.0	224
57	3-Mercaptopropionic Acid Capped Ga ₂ Se ₃ nanocrystal-CYP3A4 Biosensor for the Determination of 17-Alpha-Ethinyl Estradiol in Water. Nano Hybrids, 0, 1, 1-22.	0.3	8
58	Prooxidant-Induced Glutathione Antioxidant Response <i>in Vitro</i> and <i>in Vivo</i> : A Comparative Study between Schisandrin B and Curcumin. Biological and Pharmaceutical Bulletin, 2012, 35, 464-472.	0.6	15
59	The Nuremberg Code subverts human health and safety by requiring animal modeling. BMC Medical Ethics, 2012, 13, 16.	1.0	57
60	Practical use of the regression offset approach for the prediction of <i>in vivo</i> intrinsic clearance from hepatocytes. Xenobiotica, 2012, 42, 841-853.	0.5	77
61	Pharmacokinetic Drug Interactions Involving Vortioxetine (Lu AA21004), a Multimodal Antidepressant. Clinical Drug Investigation, 2013, 33, 727-736.	1.1	78
62	The utility of cold-preserved human hepatocytes in studies on cytochrome P450 induction and hepatic drug transport. Xenobiotica, 2013, 43, 785-791.	0.5	1
63	Fluorescence-Based Screening of Cytochrome P450 Activities in Intact Cells. Methods in Molecular Biology, 2013, 987, 135-148.	0.4	6
64	Metabolism Studies In Vitro and In Vivo. , 2013, , 1053-1094.		3
65	Incorporating Population Variability and Susceptible Subpopulations into Dosimetry for High-Throughput Toxicity Testing. Toxicological Sciences, 2014, 142, 210-224.	1.4	71
66	Liver tissue engineering. , 2014, , 565-588.		1
67	A cocktail approach for assessing the in vitro activity of human cytochrome P450s: An overview of current methodologies. Journal of Pharmaceutical and Biomedical Analysis, 2014, 101, 221-237.	1.4	81
68	HepaRG cell line as an in vitro model for screening drug-drug interactions mediated by metabolic induction: Amiodarone used as a model substance. Toxicology in Vitro, 2014, 28, 1531-1535.	1.1	11
69	Human Recombinant Cytochrome P450 Enzymes Display Distinct Hydrogen Peroxide Generating Activities During Substrate Independent NADPH Oxidase Reactions. Toxicological Sciences, 2014, 141, 344-352.	1.4	14
70	Characterization of <i>in vitro</i> metabolites of TM62, a potential antitumor drug, in rat, dog and human liver microsomes using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2014, 28, 2162-2170.	0.7	7
71	Impact of 17-alpha-hydroxyprogesterone caproate on cytochrome P450s in primary cultures of human hepatocytes. American Journal of Obstetrics and Gynecology, 2014, 211, 412.e1-412.e6.	0.7	3
72	Serum-free culture of primary human hepatocytes in a miniaturized hollow-fibre membrane bioreactor for pharmacological <i>in vitro</i> studies. Journal of Tissue Engineering and Regenerative Medicine, 2015, 9, 1017-1026.	1.3	43
73	Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. Drug Metabolism Reviews, 2015, 47, 470-519.	1.5	58

#	ARTICLE	IF	CITATIONS
74	Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 857-868.	1.5	17
75	Human hepatoma cell lines on gas foaming templated alginate scaffolds for in vitro drug-drug interaction and metabolism studies. <i>Toxicology in Vitro</i> , 2015, 30, 331-340.	1.1	8
76	Comparison of Liver Cell Models Using the Basel Phenotyping Cocktail. <i>Frontiers in Pharmacology</i> , 2016, 7, 443.	1.6	75
77	A Rapid and Sensitive HPLC-DAD Assay to Quantify Lamotrigine, Phenytoin and Its Main Metabolite in Samples of Cultured HepaRG Cells. <i>Journal of Chromatographic Science</i> , 2016, 54, 1352-1358.	0.7	5
78	Simultaneous quantification of vortioxetine, carvedilol and its active metabolite 4-hydroxyphenyl carvedilol in rat plasma by UPLC-MS/MS: Application to their pharmacokinetic interaction study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 128, 184-190.	1.4	15
79	Primary-like human hepatocytes genetically engineered to obtain proliferation competence display hepatic differentiation characteristics in monolayer and organotypical spheroid cultures. <i>Cell Biology International</i> , 2016, 40, 341-353.	1.4	24
80	Comparative Metabolism Study of Five Protoberberine Alkaloids in Liver Microsomes from Rat, Rhesus Monkey, and Human. <i>Planta Medica</i> , 2017, 83, 1281-1288.	0.7	14
81	Comparison of methods for the prediction of human clearance from hepatocyte intrinsic clearance for a set of reference compounds and an external evaluation set. <i>Xenobiotica</i> , 2017, 47, 741-751.	0.5	30
82	Evaluation of the tissue distribution, excretion, and cytochrome P450 induction studies of a potential antitumor agent, TM-2, in animals using LC-MS/MS. <i>Xenobiotica</i> , 2017, 47, 800-806.	0.5	2
83	Human and mouse artificial chromosome technologies for studies of pharmacokinetics and toxicokinetics. <i>Drug Metabolism and Pharmacokinetics</i> , 2018, 33, 17-30.	1.1	19
84	Metabolic Barrier of the Gastrointestinal Tract. , 2018, , 74-98.		3
85	Finding synergies for 3Rs Toxicokinetics and read-across: Report from an EPAA partners' Forum. <i>Regulatory Toxicology and Pharmacology</i> , 2018, 99, 5-21.	1.3	31
86	Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects. <i>Supportive Care in Cancer</i> , 2019, 27, 819-827.	1.0	12
87	Simultaneous Determination of Rivaroxaban and Enalapril in Rat Plasma by UPLC-MS/MS and Its Application to A Pharmacokinetic Interaction Study. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2019, 44, 229-236.	0.6	8
88	Comparison of mRNA expression profiles of drug-metabolizing enzymes and transporters in fresh and cryopreserved cynomolgus monkey hepatocytes. <i>Drug Metabolism and Pharmacokinetics</i> , 2019, 34, 253-263.	1.1	1
89	Metabolic activity testing can underestimate acute drug cytotoxicity as revealed by HepG2 cell clones overexpressing cytochrome P450 2C19 and 3A4. <i>Toxicology</i> , 2019, 412, 37-47.	2.0	20
90	Decomposition profile data analysis of multiple drug effects identifies endoplasmic reticulum stress-inducing ability as an unrecognized factor. <i>Scientific Reports</i> , 2020, 10, 13139.	1.6	12
91	Hepatocytes and Their Role in Metabolism. , 0, , .		3

#	ARTICLE	IF	CITATIONS
92	Identification of novel potential inhibitors of varicella-zoster virus thymidine kinase from ethnopharmacologic relevant plants through an in-silico approach. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021, , 1-16.	2.0	2
93	In vitro assessments predict that CYP3A4 contributes to a greater extent than CYP3A5 to prednisolone clearance. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 129, 427-436.	1.2	2
94	Metabolism Studies in vitro and in vivo. , 2006, , 493-520.		6
95	Drug-Drug Interaction-Enzyme Inhibition. , 2006, , 551-557.		2
96	Modifications of the 7-Hydroxyl Group of the Transthyretin Ligand Luteolin Provide Mechanistic Insights into Its Binding Properties and High Plasma Specificity. <i>PLoS ONE</i> , 2016, 11, e0153112.	1.1	14
97	Establishment of a novel hepatocyte model that expresses four cytochrome P450 genes stably via mammalian-derived artificial chromosome for pharmacokinetics and toxicity studies. <i>PLoS ONE</i> , 2017, 12, e0187072.	1.1	16
98	Applications of AmpliChip CYP450. <i>Molecular Diagnosis and Therapy</i> , 2005, 9, 119-127.	1.2	79
99	The Comparison of Rat and Human Intestinal and Hepatic Glucuronidation of Enterolactone Derived from Flaxseed Lignans. <i>Natural Products Journal</i> , 2013, 3, 159-171.	0.1	10
100	Metabolic stability and its role in the discovery of new chemical entities. <i>Acta Pharmaceutica</i> , 2019, 69, 345-361.	0.9	60
101	Investigation of in Vitro and in Vivo Metabolism of Schisandrin B from Schisandrae Fructus by Liquid Chromatography Coupled Electrospray Ionization Tandem Mass Spectrometry. <i>Pharmacology & Pharmacy</i> , 2015, 06, 363-373.	0.2	4
102	Age-associated changes of cytochrome P450 and related phase-2 gene/proteins in livers of rats. <i>PeerJ</i> , 2019, 7, e7429.	0.9	43
103	DRUG METABOLISM Metabolite Isolation and Identification. , 2005, , 305-311.		2
104	Drug Interactions of Grapefruit and Other Citrus_What Have We Learned?. <i>Drugs and the Pharmaceutical Sciences</i> , 2006, , 147-190.	0.1	0
105	Modes of Action at Target Sites. , 2006, , 415-440.		0
106	Chapter 13. Drug Biotransformation. , 2009, , .		0
107	Regulation of Human CYP2D6. , 2016, , 315-340.		0
108	Modes of Action at Target Sites. , 2016, , 431-456.		2
109	Validated UPLC-MS/MS Method for the Simultaneous Quantification of Vortioxetine and Fluoxetine in Plasma: Application to Their Pharmacokinetic Interaction Study in Wistar Rats. <i>American Journal of Analytical Chemistry</i> , 2020, 11, 233-259.	0.3	1

#	ARTICLE	IF	CITATIONS
110	<i>In vitro</i> Metabolic Stability of Drugs and Applications of LC-MS in Metabolite Profiling. , 0, , .		1
111	ï¿½Synthesis, in silico prediction of sites of metabolism and in-vitro hepatotoxicity evaluation of new series of N ⁶ -substituted 3-(1,3,7-trimethyl-xanthin-8-ylthio)propanehydrazides. Pharmacia, 2022, 69, 351-361.	0.4	1
112	Discovery of Rift Valley fever virus natural pan-inhibitors by targeting its multiple key proteins through computational approaches. Scientific Reports, 2022, 12, .	1.6	13
113	In Silico and In Vitro Screening Constituents of Eclipta alba Leaf Extract to Reveal Antimicrobial Potential. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-14.	0.5	3
114	Immobilization of cytochrome P450 enzymes onto magnetic beads: An approach to drug metabolism and biocatalysis. Talanta Open, 2023, 7, 100181.	1.7	4
115	In Vitro Hepatic Models to Assess Herb-Drug Interactions: Approaches and Challenges. Pharmaceuticals, 2023, 16, 409.	1.7	3